Search - tctmd.com

Displaying 121 - 140 of 516

Sort: Relevancy | Date

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

News Conference News TCT 2021

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

Shelley Wood

November 04, 2021

News Conference News TCT 2021

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

Yael L. Maxwell

November 04, 2021

News Conference News TCT 2021

FAVOR III China Adds Strength to Value of QFR-Guided PCI

L.A. McKeown

November 04, 2021

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

News Daily News

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Caitlin E. Cox

September 15, 2021

News Daily News

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

L.A. McKeown

September 07, 2021

News Conference News ESC 2021

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

Shelley Wood

September 02, 2021

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

News Conference News

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

Shelley Wood

August 30, 2021

News Conference News ESC 2021

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Shelley Wood

August 28, 2021

News Conference News ESC 2021

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

Todd Neale

August 24, 2021

News Opinion Editor's Corner ESC 2021

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

Shelley Wood

August 19, 2021

News Daily News

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

Yael L. Maxwell

July 16, 2021

News Conference News EAS 2021

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

Michael O'Riordan

June 08, 2021

News Conference News ACC 2021

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

Yael L. Maxwell

May 26, 2021

News Conference News EuroPCR 2021

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

Michael O'Riordan

May 19, 2021

News Conference News ACC 2021

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Yael L. Maxwell

May 17, 2021

News Conference News ACC 2021

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

L.A. McKeown

May 16, 2021

News Conference News ACC 2021

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Yael L. Maxwell

May 15, 2021

Advertisement

More DAPT Duration Data, More Calls to Tailor to Individual Patients

OCT Guidance Cuts Stent Use in STEMI Without Plaque Rupture: EROSION III

‘Sweet Like SUGAR’: Polymer-Free Stent Noninferior to ZES in Diabetic Patients

FAVOR III China Adds Strength to Value of QFR-Guided PCI

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

DCB Match DES for Treating Coronary In-Stent Restenosis: European Registry

Lidocaine Less Likely Than Fentanyl to Blunt P2Y12 Inhibitors in the Cath Lab

OAC Analysis From MASTER DAPT Raises No Red Flags for Shorter DAPT

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

In ACS, Clopidogrel Monotherapy After 1-Month DAPT Falls Short: STOPDAPT-2 ACS

MASTER DAPT: One Month's Enough in Patients at High Bleeding Risk

Prasugrel Tops Ticagrelor in ACS Across the eGFR Spectrum: ISAR-REACT 5

ESC 2021: Trials, Guidelines, and Channel Surfing at This Year’s Virtual Congress

De-escalation Tops Other DAPT Tactics for ACS: Meta-analysis

High Ischemic Risk and Bleeding Risk: A Delicate Balance Post-PCI

Extended TAILOR-PCI Data Again Show No Gains for Genotype-Guided Meds

FUTURE II: A Good ‘First Step’ for Thinner-Strut Bioresorbable Scaffold

TALOS-AMI Supports Clopidogrel De-escalation After Earlier Ticagrelor Post-PCI

Clopidogrel, Not Aspirin, for Post-DAPT Monotherapy After PCI: HOST-EXAM

Ticagrelor Monotherapy’s Benefits Extend to Women in TWILIGHT

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content